Juan Gómez Rivas, Associate Professor at Complutense University of Madrid, shared on X about a paper he co-authored with colleagues, published in European Urology Open Science:
“Breaking the ice with Big Data in prostate cancer research!
Our latest study from the PIONEER+ Big Data Investigation Group, just published in European Urology Open Science, analyzed nearly 70,000 men with metastatic hormone-sensitive prostate cancer (mHSPC) across Europe and North America.
Highlights:
- Most common comorbidities: hypertension (up to 71%), obesity (46%), and diabetes (32%).
- Older patients (70–79 yrs): more often received ADT monotherapy or ADT plus ARPI.
- Younger patients (60–69 yrs): more often treated with ADT plus chemotherapy or triplet therapy.
- From 2016–2020: steady rise in ADT plus ARPI use, decline in ADT plus chemotherapy, while ADT monotherapy remained stable.
Key message: Age and comorbidities are major drivers of treatment choice, and real-world evidence is essential to guide equitable, evidence-based care.
Once again, PIONEER keeps breaking the ice in the way we do research.”
Title: Real-world Evidence on Baseline Characteristics and Treatment in Metastatic Hormone-sensitive Prostate Cancer: Findings from the PIONEER 2.0 Big Data Investigation Group
Authors: Juan Gómez Rivas, Pia Kraft, Susan Evans-Axelsson, Ayman Hijazy, Katharina Beyer, Bertrand De Meulder, Alex Qinyang Liu, Asieh Golozar, Artsiom Harbachou, Qi Feng, Robert Snijder, Carl Steinbeisser, Sebastiaan Remmers, Giorgio Gandaglia, Pawel Rajwa, Daniel Kotik, Veeru Kasivisvanathan, Muhammad Omar, Jesús Moreno Sierra, Alberto Briganti, Rossella Nicoletti
You can read the Full Article in European Urology Open Science.
More posts featuring Juan Gómez Rivas.